Japanese cedar pollinosis
Conditions
Interventions
Pre-co-seasonal sublingual immunotherapy
Year-round sublingual immunotherapy
Sponsors
International University of Health and Welfare
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with Japanese cedar pollinosis who started sublingual immunotherapy with cedar sublingual tablets (Cedarcure) during the year 2024 2.Patients who are maintained on sublingual immunotherapy with Cedarcure 5,000 JAU tablets 3.Patients with a serum cedar-specific IgE class of 2 or higher 4.Patients who can obtain written consent from themselves to participate in the study of their own free will 5.Patients who are 5 years or older at the time of consent 6.Gender: Not specified 7.Outpatient
Exclusion criteria
Exclusion criteria: 1.Women who are pregnant or may become pregnant 2.Patients diagnosed with cancer 3.Patients taking oral steroids (more than 10 mg/day of prednisolone for more than two consecutive weeks) 4.Patients receiving omalizumab, dupilumab, mepolizumab, benralizumab, or tezepelumab 5.Patients with severe asthma 6.Patients with a history of anaphylaxis 7.Patients with a history of hypersensitivity to adrenaline 8.Patients judged to have complications or infections that affect the heart, liver, kidneys, blood diseases, or other conditions that could impact the conduct of the study 9.Patients deemed unsuitable for study participation by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total nasal symptom score over one Week during the peak of the pollen season | — |
Countries
Japan
Contacts
Public ContactMaiko Maruyama
International University of Health and Welfare Otorhinolaryngology, Head and Neck Surgery
Outcome results
None listed